Audit/research project for follow-up cystoscopy superficial bladder cancer
| ISRCTN | ISRCTN24647129 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN24647129 |
| Protocol serial number | SUPBLACAN |
| Sponsor | NHS R&D Regional Programme Register - Department of Health (UK) |
| Funder | NHS Executive Northern and Yorkshire (UK) |
- Submission date
- 23/01/2004
- Registration date
- 23/01/2004
- Last edited
- 24/10/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr R Hall
Scientific
Scientific
Freeman Hospital
Newcastle
NE7 7DN
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Audit/research project for follow-up cystoscopy superficial bladder cancer |
| Study objectives | 1. To conduct an audit of a new programme of cystoscopic follow-up for patients with Ta. T1 bladder carcinoma. 2. To conduct a randomised comparison of: 2.1. Mitocytin-C versus epirubicin as single intravesical instillations at the time of diagnosis to evaluate relative efficacy in prevention of recurrent bladder cancer 2.2. A single instillation of intravesical chemotherapy (MMC or Epi) versus five instillations (to be given at the time of each follow-up cystoscopy for 1 year) to determine the relative efficacy in reducing tumour recurrence in medium risk Ta.T1 bladder cancer. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Cancer (neoplasms): Bladder (superficial) |
| Intervention | Not provided at time of registration |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Mitocytin-C versus Epirubicin |
| Primary outcome measure(s) |
1.1 Number of unplanned incidents (return with symptoms, need for unscheduled cystoscopies or tumour resections). |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 15/05/1997 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 16/05/1994 |
| Date of final enrolment | 15/05/1997 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Freeman Hospital
Newcastle
NE7 7DN
United Kingdom
NE7 7DN
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
24/10/2019: No publications found. All search options exhausted.